<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00152256</url>
  </required_header>
  <id_info>
    <org_study_id>C02-037</org_study_id>
    <nct_id>NCT00152256</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate of the Safety and Effectiveness of Asoprisnil in Treating Women With Uterine Fibroids</brief_title>
  <official_title>A Phase 3,6-Month, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Two Doses of Asoprisnil Versus Placebo in Subjects With Uterine Leiomyomata</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to determine the safety and efficacy effects of two doses of
      asoprisnil (10 mg and 25 mg) compared with placebo when administered daily for 6 months to
      premenopausal subjects with symptomatic uterine leiomyomata.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      No medical therapy is currently available for the long-term treatment of abnormal uterine
      bleeding associated with uterine fibroids. Asoprisnil (10 mg and 25mg) is being evaluated in
      a Phase 3 program to establish long term safety and effectiveness and therefore provide women
      with a medical alternative to surgery.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2003</start_date>
  <completion_date type="Actual">February 2005</completion_date>
  <primary_completion_date type="Actual">February 2005</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative percent of subjects achieving amenorrhea.</measure>
    <time_frame>Month 3</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in total symptom severity score and the Uterine Fibroid Symptom-Quality of Life total score.</measure>
    <time_frame>Final Visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in menorrhagia, metrorrhagia, bloating, pelvic pressure, dysmenorrhea, pelvic pain and urinary symptoms.</measure>
    <time_frame>Final Visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the Work Limitation Questionnaire Index.</measure>
    <time_frame>Final Visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the two dimensions of the SF-36 (Physical Component Summary and Mental Component Summary).</measure>
    <time_frame>Final Visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the monthly bleeding score.</measure>
    <time_frame>Final Visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the hemoglobin concentration.</measure>
    <time_frame>Final Visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in volume of the largest fibroid.</measure>
    <time_frame>Final Visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects who discontinue with the intent to have surgery for fibroids during treatment.</measure>
    <time_frame>During treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects who respond positively to the global efficacy question.</measure>
    <time_frame>Final Visit</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">239</enrollment>
  <condition>Fibroid Uterus</condition>
  <condition>Leiomyoma</condition>
  <condition>Menorrhagia</condition>
  <condition>Metrorrhagia</condition>
  <condition>Uterine Fibroids</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Asoprisnil</intervention_name>
    <description>Asoprisnil 10 mg Tablet, oral Daily for 6 months</description>
    <arm_group_label>1</arm_group_label>
    <other_name>J867</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Asoprisnil</intervention_name>
    <description>Asoprisnil 25mg Tablet, oral Daily for 6 months</description>
    <arm_group_label>2</arm_group_label>
    <other_name>J867</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo Tablet, oral Daily for 6 months</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Premenopausal women

          -  History of regular menstrual cycles (21-42 days)

          -  Diagnosis of uterine fibroid(s)

          -  Abnormal vaginal bleeding associated with uterine fibroids

          -  Otherwise in good health

          -  Subject must have at least one fibroid with a diameter ≥ 2 cm or multiple small
             fibroids with a uterine volume of ≥ 200 cm3

        Exclusion Criteria:

          -  Less than 3 months postpartum and post-lactation

          -  Previous myomectomy within 1 year

          -  Any abnormal lab or procedure result the study-doctor considers important

          -  Severe reaction(s) to or are currently using any hormone therapy

          -  History of osteoporosis or other bone disease
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>53 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Chair</role>
    <affiliation>Abbott</affiliation>
  </overall_official>
  <verification_date>May 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 7, 2005</study_first_submitted>
  <study_first_submitted_qc>September 7, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2005</study_first_posted>
  <last_update_submitted>May 27, 2008</last_update_submitted>
  <last_update_submitted_qc>May 27, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 29, 2008</last_update_posted>
  <responsible_party>
    <name_title>Cynthia Mattia-Goldberg</name_title>
    <organization>Abbott</organization>
  </responsible_party>
  <keyword>Symptomatic Uterine Fibroids</keyword>
  <keyword>Excessive Uterine Bleeding</keyword>
  <keyword>Uterine Hemorrhage</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leiomyoma</mesh_term>
    <mesh_term>Myofibroma</mesh_term>
    <mesh_term>Menorrhagia</mesh_term>
    <mesh_term>Metrorrhagia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

